Background: Plasma levels of L-arginine have previously been evaluated in several studies to reveal either down- or up-regulation of the L-arginine/NO pathway in chronic uremia.
Material/methods: We studied L-arginine plasma levels along with intracellular neutrophil concentration and NO release by peripheral blood neutrophils in patients with chronic uremia.
Results: The L-arginine plasma concentration was found to be significantly higher (64.4 +/- 12.0 micromol/L) in chronic uremic patients (n=25) than in healthy controls (33.0? +/- 10.0 micromol/L; n=25). Neutrophil homogenate L-arginine levels were substantially increased in uremic patients (7.95? +/- 1.10 nmol/10(8) cells) as compared with controls (5.22 +/- 0.46 nmol/10(8) cells). The in vitro release of NO by unstimulated neutrophils was lower in uremic patients (0.14? +/- 0.05? micromol s(-1)) than in healthy persons (0.48 +/- 0.20 micromol s-1). The NO release after uremic neutrophil stimulation with 10(-6) M fMLP was 21.42 +/- 2.13 micromol s(-1), while after PMA it was 31.01 +/- 1.99 micromol s(-1). NO release after normal neutrophil stimulation with 10(-7) M fMLP was 19.52 +/- 2.32 micromol s(-1), and after PMA was 28.63 +/- 3.06 micromol s(-1).
Conclusions: In chronic uremic patients plasma and neutrophil concentrations of L-arginine were significantly higher. However, there were no significant differences in NO release between normal and uremic neutrophils after stimulation. Our findings may have implications for the impact of the L-arginine-nitric oxide signaling pathway on the pathophysiological changes in the L-arginine: NO pathway seen in chronic uremia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Uremic Leontiasis Ossea: A Challenge in End-Stage Chronic Kidney Disease. About a Case].
Rev Med Chil
May 2024
Departamento de Nefrología, Clínica Dávila, Santiago, Chile.
Unlabelled: Uremic leontiasis ossia (ULO) is a rare manifestation of renal osteodystrophy in) patients with end-stage chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPTH). It occurs due to increased osteoclastic activity secondary to high plasmatic parathyroid hormone (PTH) levels. This leads to bone deformation with thickening and massive enlargement of the cranial vault, resulting in a leonine face appearance.
View Article and Find Full Text PDFLeontiasis ossea in the setting of chronic kidney disease and limited dialysis access: A case report with discussion of therapeutic implications.
Radiol Case Rep
March 2025
Department of Family Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.
Leontiasis ossea, also known as craniofacial fibrous dysplasia, is a rare form of osseous hypertrophy of the facial bones associated with chronic kidney disease and secondary hyperparathyroidism. As the condition progresses, changes in bone structure can lead to severe facial disfigurement, respiratory difficulties, dysarthria, and dysphagia. We describe the case of an approximately 30-year-old male with a long-standing history of end-stage renal disease who experienced rapidly progressing facial swelling and underlying bone changes following a period of poor access to dialysis.
View Article and Find Full Text PDFHow Uremic Toxins Alter Atorvastatin Disposition: Molecular Mechanisms of Inhibition of the Enzyme CYP3A4.
Balkan Med J
January 2025
Department of Clinical Pharmacy, China Pharmaceutical University, School of Basic Medicine and Clinical Pharmacy, Nanjing, China.
Article Synopsis
- Uremic patients accumulate protein-bound uremic toxins (PBUTs), which alter drug metabolism by affecting the environment around liver cells and CYP450 enzymes.
- The study found that specific PBUTs like indoxyl sulfate (IS) and hippurate (HA) significantly inhibit the metabolism of atorvastatin (ATV), with IS being the most impactful, reducing ATV metabolism by over 50%.
- Results showed that the expression of the enzyme CYP3A4, critical for drug metabolism, was downregulated in the presence of uremic serum, leading to decreased ATV uptake and excretion due to effects on related signaling pathways.
Alterations in structural and functional connectivity of thalamic subregions in patients with uremic pruritus undergoing peritoneal dialysis.
Neuroscience
December 2024
Department of Medical Imaging, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address:
Uremic pruritus (UP) significantly compromises the quality of life in patients with end-stage renal disease undergoing peritoneal dialysis. Although the precise pathophysiological mechanisms of UP remain elusive, the thalamus, which is integral to processing sensory information, is potentially implicated in its development. This study aimed to investigate alterations in the structure and resting-state functional connectivity (rsFC) of thalamic subregions in patients with UP.
View Article and Find Full Text PDFAssociation between serum total indoxyl sulfate, intraperitoneal inflammation, and peritoneal dialysis technique failure: a 3-year prospective cohort study.
BMC Nephrol
December 2024
Head Doctor of the Dialysis Medical Center LLC, "Nephrocenter", Dovzhenka 3, Kyiv, 03057, Ukraine.
Background: The impact of protein-bound uremic toxins, specifically indoxyl sulfate (IS) on peritoneal dialysis (PD) complications remains controversial. This study aimed to explore the link between serum total IS (tIS) levels, proinflammatory cytokines in serum and peritoneal dialysis effluent (PDE), and PD technique survival.
Methods: In this prospective cohort study, 84 patients were followed up for three years and analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!